Evogene Ltd. — Investor Presentation 2022

Apr 26, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2022

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 AgPlenus Investor Presentation. Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: April 26, 2022 By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

Forward-Looking Statements

This presentation contains forward-looking to future events, and AgPenus (the "Company ) and its parent, and collectively" we", "us", "ou", our", on", our", on", our", on", o from time to ther statements, reqarding our outlook or expectations for future financial or operating or affecting or affecting or affecting or affecting or affecting or affe "forward-looking statements" as defined in the U.S. Printer P.C.o 1995 (the "PS.RA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "exped", "antimated", "intent" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value diver, growing mallenges, business model and potential revenue stream, commercalization effors and tining, probut development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology,

Such statements are based on current expections and assumptions, descibe opiniors about iture events, involve certain risk and uncertaining which and uncertaining which and u pedict and are not quarantees of future performance or achevenents, and trends in the future may difer materially from what is expessed or implied by such fonnad-looking statements due to a variety of including, without linitition, those described in greater detail in creater detail in creater detail in Erogene' Report on Form 20-F and in other information Evogenites Autority and the U.S. Securities and Echange Commissor, including those foctors under the heading "Risk Factors".

Except as required by applicable securities laws we commisment to update any information contained in this presentation or to publicy release of any revisions to any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herin does not constitute a prospectus or other of constitute or form part of any invitation of offer to sell, or any soliciation of any invitation of offer to purchas or subscrites of Evopene or the Company, nor shall the information or any part of its distribution form the basis of o be relief on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the are used for reference purposes only. Such use should not be construed an endorsement of our products or services.

Agenda

• · Company introduction
• · Business model
• · Product pipeline
• Technology
• Milestone roadmap

We design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry

Growing market for crop protection products with need for innovation

Chemicals-Market-Size-Share-Will-Reach-to-USD-90-Billion-by-2

-- agPlenus - 5 -

Lack of new Mode-of-Action (MoAs) for 3 decades Major Ag companies have failed to meet the demand for innovation

All rights reserved to AgPlenus Ltd. ©

Herbicide resistant weeds have flourished

• · Overuse of existing MoAs has generated selection pressure
  • · 263 herbicide-resistant weed species have evolved*
• · Substantial economic cost to farmers
  • · Increase costs and reduce yields
  • · United States: Soybeans: \$35/acre additional costs **

The challenge:

There have been no commercial herbicides with a new MoA for over 30 years™

Sources: * https://weedscience.org/Home.aspx

** Herbicide resistant weeds cost farmers millions | F *** Focus on Weed Control: Herbicides as Technology: The Path to Modern Agriculture - PMC (nih.gov)

• "agPlenus - 6 -

AgPlenus' target-based technology addresses the challenges

All rights reserved to AgPlenus Ltd. ©

Discovery

Identification of untapped biological pathways leads to new MoA as required by the industry to circumvent ongoing resistance challenges.

Computational selection produces the most promising candidates with the widest structural variety to enable fine tuning of products based on partner and end user needs.

Optimization

Computationally driven solutions addressing optimization development challenges for the selected candidates reduce time and cost to the market to substantially increase the probability of success.

Powered by: Chem evogene

Innovative & experienced management team

Experienced board of directors

Dr. Brian Ember CEO

Previous positions:

• · Biotalys, Head of Global Portfolio Management and Head of Marketing
• · AgriMetis,
• · Business Development

Ofer Haviv Chairman of the board

· Evogene, President & CEO

Dr. Merav Beiman VP R&D

Previous positions:

• · ImmPACT-Bio, CEO · Ferring, R&D
• · Compugen, R&D
• · QBI, R&D

Robert A. Woods ·Marrone Bio Innovations, Inc., Chairman · Bioenterprise capital private equity · Previously, Syngenta, President USA

Mirit Ram VP of Project Management

Previous positions:

• · Evogene, PM
• · FMC, PM
• · HP

Eran Kosover

• · Previously AgPlenus Ltd., CEO
• · Evogene EVP & GM Crop Protection, Evogene VP of collaborations,
• · Atera Networks

Agenda

• · Company introduction
• · Business model
• · Product pipeline
• Technology
• Milestone roadmap

Crop protection industry

· Dominated by Major ag-chemical companies

• · 62%* of ag-chemical crop protection market share (Bayer, BASF, Corteva, Syngenta)
• · Pace of innovation and new product introductions have slowed

• Looking to smaller, ag-tech companies to develop new small-molecule candidates

  • · AgPlenus is leading the integration of computational technology to discover small molecules
  • · Focusing on developing products with new MoAs

• Source: https://belonging.berkeley.edu/era-corporate-consolidation-and-end-competition

Product development stages

------ "agPlenus - 11 --

Value creation through product development process

As products are developed to a greater extent, technical risks decline creating more value.

Business model & potential revenue stream

Corteva collaboration

· Develop new MoA herbicides to target resistant weeds

• · Started in March 2020
• · AgPlenus will discover and optimize herbicide candidates
• · Corteva will conduct testing and product development

· License to Corteva

• · Corteva has exclusive license to products of collaboration
• · AgPlenus receives research fees, milestones and royalties upon commercialization

Agenda

• · Company introduction
• · Business model
• · Product pipeline
• Technology
• Milestone roadmap

Products under development

https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html

-- "agPlenus - 16 -

AgPlenus product pipeline

APTH-AgPlenus target herbicide, APH-AgPlenus herbicide, APTI-AgPlenus target Insecticide, S-Scaffold

All rights reserved to AgPlenus Ltd. ©

-- "agPlenus -

APH 1 (APTH1/Scaffold1) - New MoA herbicide reached Lead stage

• · Broad-spectrum weed control at commercial dosage rates
• · Effective against resistant weed strains including Palmer Amaranth

(16DAA) (Rehovot, Israel)

APH 1 (APTH1/Scaffold1)

New MoA Herbicide active at commercial concentrations

---

APH 1 (APTH1/Scaffold1) - Product candidate efficacy

• agPlenus - 20 -

Broad activity, pre and post application

Agenda

• · Company introduction
• · Business model
• · Product pipeline
• · Technology
• Milestone roadmap

AgPlenus technology empowered by Evogene's ChemPass Al

Computational prediction of multiple product attributes

From Target to an Optimized Lead

All rights reserved to AgPlenus Ltd. ©

-- agPlenus - 24 --

Experimental pipeline up to Lead stage

All rights reserved to AgPlenus Ltd. ©

---

Agenda

• · Company introduction
• · Business model
• · Product pipeline
• Technology
• · Milestone roadmap

Expected main near-term value drivers

2022

New MoA herbicides -.

• · Enter an additional collaboration agreement
• New MoA herbicide -.
• · Expand data package for APTH1, AgPlenus' leading new MoA protein for the development of novel herbicides

2023

• · New MoA herbicides -
• · Reach milestone in one of the ongoing collaborations
• · New MoA fungicide -
• · Initial greenhouse readouts

We are AgPlenus

Creating effective and sustainable crop protection products

© THANK YOU